Literature DB >> 27417921

Systemic disease manifestations associated with epilepsy in tuberous sclerosis complex.

Anna Jeong1, Michael Wong1,2.   

Abstract

OBJECTIVE: Epilepsy is one of the most disabling symptoms of tuberous sclerosis complex (TSC) and is a leading cause of morbidity and mortality in affected individuals. The relationship between systemic disease manifestations and the presence of epilepsy has not been thoroughly investigated. This study utilizes a multicenter TSC Natural History Database including 1,816 individuals to test the hypothesis that systemic disease manifestations of TSC are associated with epilepsy.
METHODS: Univariate analysis was used to identify patient characteristics (e.g., age, gender, race, and TSC mutation status) associated with the presence of epilepsy. Individual logistic regression models were built to examine the association between epilepsy and each candidate systemic or neurologic disease variable, controlling for the patient characteristics found to be significant on univariate analysis. Finally, a multivariable logistic regression model was constructed, using the variables found to be significant on the individual analyses as well as the patient characteristics that were significant on univariate analysis.
RESULTS: Nearly 88% of our cohort had a history of epilepsy. After adjusting for age, gender, and TSC mutation status, multiple systemic disease manifestations including cardiac rhabdomyomas (odds ratio [OR] 2.3, 95% confidence interval [CI] 1.3-3.9, p = 0.002), retinal hamartomas (OR 2.1, CI 1.0-4.3, p = 0.04), renal cysts (OR 2.1, CI 1.3-3.4, p = 0.002), renal angiomyolipomas (OR 3.0, CI 1.8-5.1, p < 0.001), shagreen patches (OR 1.7, CI 1.0-2.7, p = 0.04), and facial angiofibromas (OR 1.7, CI 1.1-2.9, p = 0.03) were associated with a higher likelihood of epilepsy. In the multivariable logistic regression model, cardiac rhabdomyomas (OR 1.9, CI 1.0-3.5, p = 0.04) remained significantly associated with the presence of epilepsy. SIGNIFICANCE: The identification of systemic disease manifestations such as cardiac rhabdomyomas that confer a higher risk of epilepsy development in TSC could contribute to disease prognostication and assist in the identification of individuals who may receive maximal benefit from potentially novel, targeted, preventative therapies. Wiley Periodicals, Inc.
© 2016 International League Against Epilepsy.

Entities:  

Keywords:  Cardiac rhabdomyoma; Epilepsy; Mutation status; Systemic; Tuberous sclerosis

Mesh:

Substances:

Year:  2016        PMID: 27417921     DOI: 10.1111/epi.13467

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

1.  Predictors of Drug-Resistant Epilepsy in Tuberous Sclerosis Complex.

Authors:  Anna Jeong; Jo Anne Nakagawa; Michael Wong
Journal:  J Child Neurol       Date:  2017-12       Impact factor: 1.987

2.  Incidental diagnosis of tuberous sclerosis complex by exome sequencing in three families with subclinical findings.

Authors:  R C Caylor; L Grote; I Thiffault; E G Farrow; L Willig; S Soden; S M Amudhavalli; A J Nopper; K A Horii; E Fleming; J Jenkins; H Welsh; M Ilyas; K Engleman; A Abdelmoity; C J Saunders
Journal:  Neurogenetics       Date:  2018-06-20       Impact factor: 2.660

Review 3.  Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.

Authors:  Rima Nabbout; Mathieu Kuchenbuch; Catherine Chiron; Paolo Curatolo
Journal:  CNS Drugs       Date:  2021-08-21       Impact factor: 5.749

4.  Epilepsy in Children with Tuberous Sclerosis Complex: A Prospective Observational Study in Bangladesh.

Authors:  Md Mizanur Rahman; Kanij Fatema
Journal:  J Epilepsy Res       Date:  2020-06-30

5.  Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study.

Authors:  Rima Nabbout; Elena Belousova; Mirjana P Benedik; Tom Carter; Vincent Cottin; Paolo Curatolo; Maria Dahlin; Lisa D Amato; Guillaume Beaure d'Augères; Petrus J de Vries; José C Ferreira; Martha Feucht; Carla Fladrowski; Christoph Hertzberg; Sergiusz Jozwiak; John A Lawson; Alfons Macaya; Ruben Marques; Finbar O'Callaghan; Jiong Qin; Valentin Sander; Matthias Sauter; Seema Shah; Yukitoshi Takahashi; Renaud Touraine; Sotiris Youroukos; Bernard Zonnenberg; Anna Jansen; John C Kingswood
Journal:  Epilepsia Open       Date:  2018-12-21

Review 6.  A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC).

Authors:  Johann Philipp Zöllner; David Neal Franz; Christoph Hertzberg; Rima Nabbout; Felix Rosenow; Matthias Sauter; Susanne Schubert-Bast; Adelheid Wiemer-Kruel; Adam Strzelczyk
Journal:  Orphanet J Rare Dis       Date:  2020-01-21       Impact factor: 4.123

7.  Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6.

Authors:  Joyce Y Wu; Hannah R Cock; Orrin Devinsky; Charuta Joshi; Ian Miller; Colin M Roberts; Rocio Sanchez-Carpintero; Daniel Checketts; Farhad Sahebkar
Journal:  Epilepsia       Date:  2022-03-04       Impact factor: 6.740

8.  miRNAs and isomiRs: Serum-Based Biomarkers for the Development of Intellectual Disability and Autism Spectrum Disorder in Tuberous Sclerosis Complex.

Authors:  Mirte Scheper; Alessia Romagnolo; Zein Mersini Besharat; Anand M Iyer; Romina Moavero; Christoph Hertzberg; Bernhard Weschke; Kate Riney; Martha Feucht; Theresa Scholl; Borivoj Petrak; Alice Maulisova; Rima Nabbout; Anna C Jansen; Floor E Jansen; Lieven Lagae; Malgorzata Urbanska; Elisabetta Ferretti; Aleksandra Tempes; Magdalena Blazejczyk; Jacek Jaworski; David J Kwiatkowski; Sergiusz Jozwiak; Katarzyna Kotulska; Krzysztof Sadowski; Julita Borkowska; Paolo Curatolo; James D Mills; Eleonora Aronica
Journal:  Biomedicines       Date:  2022-07-29

9.  A case report of severe tuberous sclerosis complex detected in utero and linked to a novel duplication in the TSC2 gene.

Authors:  Valérie Mongrain; Nicolaas H van Doesburg; Françoise Rypens; Catherine Fallet-Bianco; Justine Maassen; Julien Dufort-Gervais; Lucie Côté; Philippe Major
Journal:  BMC Neurol       Date:  2020-09-01       Impact factor: 2.474

10.  Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex.

Authors:  Siu Hing Lo; Jade Marshall; Hanna Skrobanski; Andrew Lloyd
Journal:  Pharmacoecon Open       Date:  2021-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.